JPWO2020215019A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020215019A5
JPWO2020215019A5 JP2021561599A JP2021561599A JPWO2020215019A5 JP WO2020215019 A5 JPWO2020215019 A5 JP WO2020215019A5 JP 2021561599 A JP2021561599 A JP 2021561599A JP 2021561599 A JP2021561599 A JP 2021561599A JP WO2020215019 A5 JPWO2020215019 A5 JP WO2020215019A5
Authority
JP
Japan
Prior art keywords
antibody
humanized anti
composition
seq
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529929A5 (https=
JP2022529929A (ja
JP7778567B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028861 external-priority patent/WO2020215019A1/en
Publication of JP2022529929A publication Critical patent/JP2022529929A/ja
Publication of JP2022529929A5 publication Critical patent/JP2022529929A5/ja
Publication of JPWO2020215019A5 publication Critical patent/JPWO2020215019A5/ja
Priority to JP2025122188A priority Critical patent/JP2025169256A/ja
Application granted granted Critical
Publication of JP7778567B2 publication Critical patent/JP7778567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561599A 2019-04-17 2020-04-17 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 Active JP7778567B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025122188A JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835349P 2019-04-17 2019-04-17
US62/835,349 2019-04-17
PCT/US2020/028861 WO2020215019A1 (en) 2019-04-17 2020-04-17 Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025122188A Division JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Publications (4)

Publication Number Publication Date
JP2022529929A JP2022529929A (ja) 2022-06-27
JP2022529929A5 JP2022529929A5 (https=) 2023-04-25
JPWO2020215019A5 true JPWO2020215019A5 (https=) 2023-04-25
JP7778567B2 JP7778567B2 (ja) 2025-12-02

Family

ID=72837950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561599A Active JP7778567B2 (ja) 2019-04-17 2020-04-17 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
JP2025122188A Pending JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025122188A Pending JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Country Status (5)

Country Link
US (1) US20230096620A1 (https=)
EP (1) EP3956358A4 (https=)
JP (2) JP7778567B2 (https=)
MA (1) MA55735A (https=)
WO (1) WO2020215019A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023095000A1 (en) * 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2026058045A1 (en) * 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
DK3277719T3 (da) * 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
JP6909208B2 (ja) * 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
WO2017106595A1 (en) * 2015-12-18 2017-06-22 Sciadonics, Inc. Lipid formulations containing bioactive fatty acids and a non-fatty acid anti-inflammatory agent
JP7162533B2 (ja) * 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
BR112019012071A2 (pt) * 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
BR112019022268A2 (pt) * 2017-04-28 2020-05-19 Millennium Pharmaceuticals, Inc. método para o tratamento de distúrbios pediátricos
US20230033021A1 (en) * 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP7331219B2 (ja) 潰瘍性大腸炎を治療する方法
JP2022188083A (ja) 化膿性汗腺炎の処置
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
US20150203592A1 (en) Compositions and methods for treating osteoarthritis
JP2024069230A5 (https=)
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
JP2023522196A (ja) 化膿性汗腺炎の治療
WO2017076804A1 (en) Treatment paradigm
JPWO2020215019A5 (https=)
WO2021060425A1 (ja) 全身性強皮症治療用医薬組成物
EP4688142A1 (en) Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP2020517648A5 (https=)
US20230338496A1 (en) Vaccination against diabetes, obesity and complications thereof
US11623003B2 (en) Vaccination against diabetes, obesity and complications thereof
JPWO2023215674A5 (https=)
WO2026060205A1 (en) PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS
US10925951B2 (en) Vaccination against diabetes, obesity and complications thereof
WO2024077113A1 (en) Methods of treating fatigue in ulcerative colitis
TW202500184A (zh) 治療潰瘍性結腸炎之方法
JPWO2022099257A5 (https=)
WO2017064564A2 (en) Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody